StonvexLoading…
StonvexStonvexStonvexQuiet session — no dominant driver
Research only. Labels above describe the current state of the stock using price, volume, and news data — they are not buy or sell recommendations. Stonvex is not a registered investment advisor. Past market behavior does not imply future results.
What you need to know right now
This is an algorithmic assessment of current technical conditions, not investment advice. Past performance does not guarantee future results.
Real-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Each row shows where INCY sits in our scored universe today on a single observational measurement. P85 means INCY ranks above 85% of peers on that factor right now. Percentile rankings are descriptive — they are not buy/sell signals or quality judgments. Universe refreshed every 60 seconds.
Today's volume vs prior session average.
Absolute daily price move vs peers.
24h article count relative to the universe.
AI-classified polarity of recent news.
Today's dollar turnover (volume × VWAP).
Signed daily return vs the rest of the universe.
Stonvex publishes percentile measurements as observational data only. Nothing here constitutes a recommendation, prediction, or advice about whether to buy, sell, or hold any security. Stonvex is not a registered investment advisor.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $1.27B | $5.14B | $3.63B | $2.27B |
Operating Income | $301.12M | $1.51B | $1.18B | $735.48M |
Net Income | $303.33M | $1.29B | $987.37M | $405.00M |
EPS (Diluted) | $1.47 | $6.41 | $4.95 | $2.84 |
Total Assets | $7.34B | $6.96B | $6.33B | $5.82B |
Total Liabilities | $1.72B | $1.79B | $1.68B | $1.65B |
Cash & Equivalents | $3.46B | $3.10B | $2.46B | $1.95B |
Free Cash Flow OCF − CapEx | Not available | Not available | Not available | Not available |
Shares Outstanding | 199.95M | 198.46M | 196.13M | 194.12M |
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-08 | $98.60 | $98.56 | -0.04% | 0.9M |
| 05-11 | $99.04 | $100.32 | +1.29% | 1.7M |
| 05-12 | $100.84 | $99.13 | -1.70% | 1.6M |
| 05-13 | $98.73 | $98.82 | +0.09% | 1.6M |
| 05-14 | $99.02 | $98.18 | -0.85% | 0.4M |
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.